Skip to main content

Table 5 Factors associated with disease-free interval (DFI) in canine invasive mammary carcinomas (n = 150)

From: The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study

Criteria

DFI: Univariate analysis

DFI: Multivariate analysis

(log-rank test) N = 150

(Cox regression model) N = 150

HR

95 % CI

p-value

HR

95 % CI

p-value

Body size

  

0.005

  

0.07

> 10 kgs

1.00

-

 

1.00

  

≤ 10 kgs

1.99

1.23–3.21

 

1.66

0.95–2.90

 

Age

  

0.007

  

0.02

<11 yrs

1.00

-

 

1.00

-

 

≥11 yrs

1.88

1.19–2.98

 

1.91

1.13–3.24

 

Multifocality

  

0.01

  

0.76

Unifocal

1.00

-

 

1.00

-

 

Multicentric

2.56

1.22–5.38

 

0.86

0.32–2.29

 

Histological grade

  

0.06

  

0.46

Grade I

1.00

-

-

1.00

-

 

Grade II

1.90

0.89–4.04

0.10

1.76

0.67–4.62

0.25

Grade III

2.43

1.17–5.06

0.02

1.83

0.69–4.86

0.22

Lymphovascular invasion

  

<0.001

  

0.04

No LVI

1.00

-

 

1.00

-

 

LVI

2.86

1.81–4.51

 

1.91

1.02–3.58

 

Surgical margins

  

0.005

  

0.15

Complete excision

1.00

-

 

1.00

-

 

Incomplete excision

1.94

1.22–3.07

 

1.57

0.85–2.88

 

Muscle infiltration

  

0.005

  

0.99

No

1.00

-

 

1.00

-

 

Yes

2.00

1.23–3.28

 

1.00

0.54–1.86

 

Peritumoral Inflammation

  

0.04

  

0.07

No

1.00

-

 

1.00

-

 

Yes

1.57

1.00–2.47

 

1.69

0.95–2.99

 

Central necrosis

  

0.03

  

0.04

No

1.00

-

 

1.00

-

 

Yes

0.56

0.34–0.93

 

0.52

0.28–0.97

 

Immunophenotype

  

0.02

  

0.18

Luminal

1.00

-

 

1.00

-

 

Triple negative

1.80

1.08–3.00

 

1.54

0.82–2.86

 

CK5/6

  

0.01

  

0.09

< 10 %

1.00

-

 

1.00

-

 

≥ 10 %

0.55

0.35–0.87

 

0.61

0.34–1.08

 

IGF1R

  

0.04

  

0.23

weak (0–1+)

1.00

-

-

1.00

-

-

moderate (2+)

1.22

0.68–2.19

0.51

1.15

0.58–2.28

0.70

strong (3+)

2.09

1.14–3.83

0.02

1.74

0.86–3.55

0.13

  1. Univariate (log rank test) and multivariate survival analyses (Cox proportional hazard regression)
  2. HR Hazard Ratio, 95 % CI 95 % Confidence Interval, CK5/6 Cytokeratin 5/6, IGF1R Insulin-like Growth Factor type 1 Receptor, LVI Lymphovascular Invasion